Next, we assessed the anti-tumour role of LATS inhibitor in ERα mutant cells and observed that VT02956 exhibited advantages over 4-OHT and Fulvestrant in inhibiting the breast cancer cells that have hormone therapy resistant hot-spot mutations, including ESR1-Y537S and ESR1-D538G (Fig. 6g, h). This evidence concerns the gene ESR1 and breast carcinoma.